MediQuality Academy

Maximum: 1 CME cr.
Sign in to view your progression
Program Overview Progr...
Learning Objectives Learn...
Target Audience Targe...
Credit Designation Credi...
Disclosure/Disclaimer Discl...

Breast cancer: towards a precision medicineSession 1 (duration : 65 min.)

Chemotherapy represents a standard treatment in the management of breast cancer. However, not all women will benefit from chemotherapy, which can be associated with major side effects and impact their quality of life. Genomic testing is a new tool for identifying patients who will benefit from chemotherapy.

  • General introduction – Challenges and limitations of chemotherapy treatment in breast cancer - Prof. Evandro de Azambuja
  • Towards a precision medicine - Predicting the probability of the benefit from chemotherapy - Dr Kevin Punie

Breast cancer: who will and who will not benefit from chemotherapy? - Session 2 (duration : 68 min.)

TAILORx, RxPONDER, Mindact are some of the studies that are leading to a real revolution in the identification of patients to whom chemotherapy should be offered. These studies have resulted in the determination of practical scores. Physicians testify about their experience.

  • Part 1 - Explanation and interpretation of the results of the main prospective randomized studies: TAILORx, RxPONDER, Mindact – Prof. Stephen Chia
  • Part 2 - Identification of patients with low/high clinical risk who may benefit from chemotherapy – Dr Donatienne Taylor
  • Part 3 - Interest of the tests in women under 50 years old – Dr Kevin Punie
  • Part 4 - Experiences of Belgian physicians who use the test – Prof. Evandro de Azambuja and Dr Donatienne Taylor

Breast cancer: genomic testing in practice - Session 3 (duration : 71 min.)

If the interest of avoiding a heavy treatment such as chemotherapy is obvious at the individual level, it is also true at the societal level from a pharmaco-economic point of view! Genomic tests are also easy to interpret ... Physicians explain how to use them routinely and how these tests can support decision-making in the treatment of breast cancer.

  • Part 1 - Health economic impact of prognostic and predictive tests – Prof. Lieven Annemans
  • Part 2.1 - Case studies - Case 1: High Ki67 - Prof. Stephen Chia
  • Part 2.2 - Case studies - Case 2 : Low clinical risk – Dr Kevin Punie
  • Part 2.3 - Case studies - Case 3 : 3 Using GEP to help deciding on the use of adjuvant chemotherapy – Prof. Evandro de Azambuja
  • Part 3 - The guidelines: test positioning – Dr Donatienne Taylor

Global objective

To raise awareness among healthcare providers about the value of genomic testing in optimizing and individualizing breast cancer management.

Specific objectives - Session 1

By the end of this module, participants will have increased their knowledge of the following topics:

  • Criteria determining the decision to treat breast cancer with chemotherapy
  • Benefits and limitations of chemotherapy
  • Principles of genomic testing
  • Predictive and prognostic value of the tests

Specific objectives - Session 2

To present the studies that led to the development of genomic tests that allow the selection of patients who will or will not benefit from chemotherapy. By the end of this module, participants will have increased their knowledge of the topics:

  • Literature underlying the development of genomic tests
  • Interest of genomic testing in patients under 50 years of age

Specific objectives - Session 3

To familiarize physicians with the use of genomic testing in clinical practice. By the end of this module, participants will have improved their knowledge of the following topics:

  • Pharmacoeconomic interest of genomic testing
  • Case Studies
  • International guidelines

These e-learning sessions are available for

  • Oncologists
  • Gynecologists
  • Anatomopathologists

In order to receive your accreditation point(s), for each sessions, please :

  • Follow the entire e-learning
  • Complete the evaluation form of this e-learning


Session 1 - Accreditation requested

Session 2 - Accredited by EACCME (number of the folder : ELM21-A00099) - 1 point

Session 3 - Accredited by EACCME (number of the folder : ELM21-A00116) - 1 point



European Accreditation Council for Continuing Medical Education

Accreditation Statement 

Accreditation by the EACCME confers the right to place the following statement in all communication materials including the registration website, the event programme and the certificate of attendance. 
The following statements must be used without revision:

The Breast cancer care and precision medicine - The right treatment for the right patient Session 2 - Who will and who will not benefit from chemotherapy?, made available on and Breast cancer: Genomic testing in practice, made available on and organized by MediQuality from Medscape Benelux, is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. 

Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Only those e-learning materials that are displayed on the UEMS-EACCME website have formally been accredited.
Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME credit to AMA credit can be found at

Prof. Evandro de Azambuja - Session 1, 2 and 3

  • Honoraria and/or advisory board from Roche/GNE, Novartis, Seattle Genetics, Zodiac, Libbs and Pierre Fabre
  • Travel grants from Roche/GNE and GSK/Novartis
  • Research grant to his institution from Roche/GNE, Astra-Zeneca, GSK/Novartis and Servier

Dr Kevin Punie - Session 1, 2 and 3

  • No personal or financial interests in Genomic Health/Exact Sciences or Agendia
  • Personal financial interests in other for-profit companies: /
  • Institutional financial interests: Astra Zeneca (Consultancy), Eli Lilly (Speaker Fees, Advisory Board), Mundi Pharma (Speaker Fee’s), Novartis (Consultancy, Advisory Board, Speaker Fee’s), Pfizer (Consultancy, Speaker Fee’s), Pierre Fabre (Advisory Board), Hoffmann/La Roche (Consultancy, Advisory Board, Speaker Fee’s), Sanofi (Research Funding), Teva (Advisory Board), Vifor Pharma (Advisory Board)
  • Travel support: Astra Zeneca, Novartis, Pfizer, PharmaMar, Hoffmann/La Roche
  • Non-financial interests: 1.Steering committee member of EORTC 1745-ETF-BCG trial (APPALACHES), 2.Committee member of ESMO Young Oncologists Committee, 3. Board member of Belgian Society of Medical Oncology (BSMO).

Prof. Stephen Chia - Session 2 and 3

  • Received honorarium: Novartis, Hoffmann LaRoche, Pfizer, Eli Lilly, AstraZeneca, Merck, Exact Sciences
  • Received research grants (to the BCCA): Novartis, Hoffmann LaRoche, Pfizer, Genomic Health, AstraZeneca, Genetech, Celgene, Amgen, BMS, Sanofi, PUMA
  • Did not receive any fees from any of these groups for this e-learning project

Dr Donatienne Taylor - Session 2 and 3

  • No financial interest in companies involved with genomic profiling tests
  • Consultancy (Honoraria): Novartis, Lilly, Roche, Daiichi Sankyo and AstraZeneca.
  • Travel grants: Pfizer, Roche, AstraZeneca

Prof. Lieven Annemans - Session 3

  • Coming soon

MediQuality - Session 1, 2 and 3

  • MediQuality requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest.
  • MediQuality encourages Authors to identify investigational products or off-label uses of products regulated by the European Food and Drug Administration, at first mention and where appropriate in the content.
  • The people working for MediQuality have disclosed that they have no relevant financial relationships.
  • MediQuality is the responsible publisher for this e-learning.
Session 1 - Breast cancer: towards a precision medicine (duration : 65 min.)
Session 2 - Who will and who will not benefit from chemotherapy? (duration : 68 min.)
Session 3 - Breast cancer: genomic testing in practice (duration : 71 min.) - (available online since june 2022)

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies